SBIR/STTR Research Award
VLR-CART Cancer Immunotherapy
Award amount
$149,036Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Novab, Inc.
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- WKYDVLA9B616
- Solicitation number
- PA14-071
- Topic code
- NCI
Research abstract
DESCRIPTION (provided by applicant): The mission of Novab is to utilize the unique properties of lamprey generated Variable Lymphocyte Receptors (VLRs) to develop effective, complementary and/or superior therapeutics to those currently derived from mammalian monoclonal antibodies (mMAbs). In the current application, we seek to initiate and demonstrate proof of concept for one commercial project within this mission, which is the application of VLRs to the design of chimeric antigen receptors (CARs) that currently are used as the tumor targeting component of genetically- engineered T cell immunotherapies. Our hypothesis is that due to independent evolution from the immunoglobulins (Igs) of jawed vertebrates, lamprey VLRs raised against therapeutic cell targets will recognize epitopes that are unique from those obtained using standard mammalian immunization and MAb (i.e. Ig) production. Therefore, VLRs represent a novel platform for the identification of cancer cell targets and the generation of improved
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Novel targeted CAR-T multiple myeloma therapy
- Novel antibody polymer reagents for SARS-CoV-2 detection
- Monoclonal antibodies specific for biologically relevant glycans
- Monoclonal lamprey VLR antibodies specific for mucin type O linked glycan core structures
- Humanization of VLR antibodies for therapeutic applications
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis
Research funding history
6 SBIR/STTR records share this UEI (2014–2023). Reported award amounts total $1,216,917. Reported amounts are not federal obligations.
Phases: Phase I
Agencies: Department of Health and Human Services